

Zoono Group Limited (ASX: ZNO)

ASX ANNOUNCEMENT

9 December 2019

Zoono joins the fight against African Swine Fever

Zoono Group Limited (ASX:ZNO) is pleased to confirm that, in research laboratory trials conducted at Wageningen Bio-Veterinary Research Department of Virology (a leading global research institute based in Lelystad, Netherlands and specialising in the prevention, eradication and control of animal diseases), ZOONO Z71 Microbe Shield was found to be extremely effective in counteracting the African Swine Fever Virus (ASF virus).

ZOONO Z71 Microbe Shield inactivated the ASF virus at better than 4 Log (a 4 Log reduction or better equates to a greater than 99.99% reduction). The AFS virus, which is a particularly difficult virus to inactivate, is decimating pig populations globally (not only within China and Korea but also in other parts of Asia and Europe).

The latest test results, which continue Zoono’s practice of having efficacy tests completed by reputable, qualified and independent GLP Laboratories, confirm the results achieved using ZOONO Z71 Microbe Shield products in the field. In conjunction with several pig producers, Zoono has been conducting trials in pig pens in China with outstanding results. Within the Zoono treated pens (after 21 days), there have been no AFS virus infections or pig fatalities, compared to numerous infected and deceased pigs in the control pens over the same 21 Day period.

Given the clinical and field research trial results, and that ZOONO Z71 Microbe Shield is a water-based product with low toxicity, Zoono believes sales and distribution opportunities will follow. To that end, following the inaugural international ASF conference held in Nanjing, China last Friday, at which many countries were represented, there has been considerable interest in the Zoono technology and products.



Figure 1: Mr. Paul Hyslop, Managing Director, Zoono Group Limited, presenting at the International ASF Conference in Nanjing last week.

For personal use only

This announcement has been approved and authorised to be given to ASX by the Board of Zoono Group Limited.

For further information, please contact:

Zoono Group Limited

Paul Hyslop

Managing Director/CEO

M: +64 21 659 977

E: paul.hyslop@zoono.com.

About Zoono

Zoono Group Limited is a global biotech company that develops, manufactures and distributes a suite of scientifically-validated, long-lasting and environmentally-friendly antimicrobial solutions. Zoono's mission is to improve health and well-being through innovative, safe, non-toxic and durable germ protection.

Zoono produces sprays, wipes and foams suited for skin care, surface sanitisers, and mould remediation treatments. The products are based on the 'zoono molecule', a unique antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mould.

Zoono's products have received numerous regulatory approvals and the company's technology claims are supported by independent testing conducted in laboratories worldwide. Zoono is headquartered in New Zealand and its products are available globally.

To learn more, please visit: www.zoono.com

About Wageningen Bio-Veterinary Research

Wageningen collaborates with public and private partners to safeguard public and animal health through prevention, eradication and control of animal diseases. It is often commissioned by the Dutch authorities, veterinary and human pharmaceutical industry, meat and dairy industry, as well as start-up companies in biotechnology, to do research. For the government, research activities consist among others of statutory tasks and other tasks related to animal health. For the private-public sector, Wageningen Bio-Veterinary Research carries out research related to vaccine development, diagnostics and animal health in general.

To learn more, please visit: <https://www.wur.nl/en.htm>